Prescient completes integration of Uptake and Dolon under single global brand

Amprion Partners with MLM Medical Labs to Expand Alpha-Synuclein SAA Testing in Europe

Amprion has announced a strategic licensing collaboration with MLM Medical Labs to expand access to alpha-synuclein seed amplification assay (SAA) testing for biopharma-sponsored clinical trials across Europe. Under the agreement, MLM will validate and perform Amprion's proprietary SAA methodology at its laboratory in Germany, supporting biomarker-driven neurodegenerative disease research and multinational clinical trials. The collaboration is intended to improve patient characterization and accelerate drug development for disorders such as Parkinson's disease, Lewy body dementia, and multiple system atrophy, while further expanding Amprion's international research capabilities.

CPHI launches new Sustainability Summit as pharma faces growing pressure to deliver sustainability goals

Broken String Biosciences launches BaseMap ABE to enable genome-wide off-target characterization in base editing therapeutic development

• Extension of the INDUCE-seq platform to support adenine base editing (ABE) workflows • Researchers invited to gain early access to platform and support ongoing product development

ECI’s Product & Packaging Testing Laboratory Achieves ISO/IEC 17025 Accreditation

ECI announced today that its Product & Packaging Testing Laboratory, located in the Coyol Free Zone in Costa Rica, has achieved ISO/IEC 17025:2017 accreditation from A2LA for technical competence in mechanical testing.

Sanofi’s MenQuadfi Wins EU Approval for Infants from Six Weeks Against Meningococcal Disease

Sanofi’s MenQuadfi has received European Commission approval for use in infants from six weeks of age against invasive meningococcal disease caused by serogroups A, C, W and Y. The expanded indication is supported by the MET58 pivotal study and clinical data involving more than 6,000 infants across 11 countries. The approval provides EU healthcare professionals with another option for early protection against a rapidly progressing and potentially fatal infection.

Proscia Receives New FDA 510(k) Clearance for Concentriq AP-Dx with Predetermined Change Control Plan

Regulatory milestone advances Proscia’s open approach to digital pathology

CellCarta Adds Tempus to CDx Commercialization Lab Network

CellCarta today announced a strategic collaboration with Tempus AI, Inc. (NASDAQ: TEM).

Inizio Launches Connected Insights to Transform Global Medical Information

CluePoints Appoints Martin Magazzolo as Chief Commercial Officer

CluePoints, provider of leading statistical and AI-driven software solutions, has appointed Martin (Marty) Magazzolo as its new Chief Commercial Officer (CCO).

Leerink Partners Report Names Carterra a Core Enabler of the $7B "Lab-in-the-Loop" Antibody Discovery Market

New research on AI-driven biologics discovery identifies Carterra's high-throughput SPR platforms as central to the Lab-in-the-Loop (LitL) workflow reshaping drug discovery, with Twist Bioscience and Adaptyv Bio pointing to surging demand for Carterra technology

Thermo Fisher Scientific Launches Thermo Scientific™ InstaFlux™ to Help Food Microbiology Labs Simplify Workflows in Pathogen and Environmental Testing

Thermo Fisher Scientific today announced the global launch of Thermo Scientific™ InstaFlux™, an integrated media-on-demand enrichment workflow that helps food microbiology laboratories simplify media preparation, improve productivity and enhance sample traceability.

ELRIG Appoints Drs Hitesh Sanganee and Marcus Schindler to Scientific Advisory Board

Leadership expansion reinforces ELRIG's commitment to delivering impactful drug discovery initiatives and driving community-wide collaboration

New leadership, new ambition: Malvern Panalytical accelerates strategy under President Christian Sauber

Backed by KKR’s £4.7 billion acquisition of Malvern Panalytical parent company Spectris, the materials characterization leader enters a new era of innovation, customer focus, and long-term ambition.

Pythia BioSciences and Lexogen Partner to Unify Multi-Omics Data Curation and Analytics with Bulk and Single-Cell RNA Sequencing

Pythia BioSciences and Lexogen formed a strategic partnership to combine Lexogen's RNA sequencing and wet-lab expertise with Pythia's multi-omics data curation, analytics, and expanding data ecosystem. The collaboration enables researchers to move from curated public datasets to custom bulk and single-cell RNA-seq experiments using biobank samples, creating analysis-ready datasets that accelerate drug discovery.

Novo Nordisk Challenges Lilly’s GLP-1 Advertising Campaigns, Claiming Consumers Are Misled by Outdated Comparisons

Novo Nordisk has filed a lawsuit against Eli Lilly, claiming that Lilly’s GLP-1 advertising campaigns use outdated comparisons and mislead consumers about obesity and diabetes treatments. The dispute focuses on advertisements comparing Zepbound® and Mounjaro® with lower doses of Wegovy® and Ozempic®. Novo Nordisk is seeking removal of the campaigns and corrective advertising to ensure patients receive updated scientific information. The case highlights increasing competition between leading pharmaceutical companies in the fast-growing GLP-1 therapy market.

MIB Agents Osteosarcoma Alliance Appoints Katherine Azima as Co-Director of Scientific Programs

MIB Agents Osteosarcoma Alliance, a nonprofit dedicated to Making It Better for the osteosarcoma community through research, education and patient support, today announced that Katherine Azima has joined the organization as Co-Director of Scientific Programs. In this role, Azima will work alongside Christina Ip-Toma, Co-Director of Scientific Programs, until Ip-Toma retires at the end of the year, to help lead and expand MIB Agents' growing portfolio of scientific initiatives, fostering collaboration among researchers, clinicians, industry partners and patient advocates to accelerate progress in osteosarcoma research.

Lilly to Acquire AtaiBeckley to Advance Innovative Biotech Therapies for Treatment-Resistant Depression

Eli Lilly and Company has announced a definitive agreement to acquire clinical-stage biotechnology company AtaiBeckley in a deal valued at up to $3.8 billion, including milestone-based payments. The acquisition significantly expands Lilly's neuroscience pipeline with innovative rapid-acting neuroplastogen therapies for treatment-resistant depression and other serious mental health disorders. The transaction highlights growing pharmaceutical investment in next-generation psychiatric medicines designed to deliver durable symptom relief through novel mechanisms of action.

Novogene Europe Launches Untargeted Metabolomics Service at Cambridge Omics Centre

• Strengthens multiomics portfolio offering metabolite-level insight to connect molecular data with biological function across broader life science studies • New workflow built around Thermo Scientific Vanquish UHPLC coupled with Orbitrap Exploris 120 high-resolution accurate-mass mass spectrometry

Sanofi Wins FDA Approval for First On-Body Injector Cancer Treatment, Making Multiple Myeloma Care Simpler

The FDA has approved Sanofi's Sarclisa Escena, making it the first anticancer therapy that can be administered through a wearable on-body injector. Clinical studies showed the new subcutaneous treatment delivers effectiveness comparable to intravenous therapy while reducing administration time and infusion-related reactions. The approval is expected to improve both patient convenience and healthcare workflow in the treatment of multiple myeloma.